Publications
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer’s disease.
Chatterjee P, Pedrini S, Ashton NJ, Tegg M, Goozee K, Singh AK, Karikari TK, Simrén J, Vanmechelen E, Armstrong NJ, Hone E, Asih PR, Taddei K, Doré V, Villemagne VL, Sohrabi HR, Zetterberg H, Masters CL, Blennow K, Martins RN. Alzheimers Dement. 2022...
Biomarker modeling of Alzheimer’s disease using PET-based Braak staging.
Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G, Servaes S, Benedet AL, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Kunach P, Wang YT, Fernandez-Arias J, Massarweh G, Vitali P, Soucy JP, Saha-Chaudhuri P, Blennow K, Zetterberg H, Gauthier S,...
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease.
Kac PR, Gonzalez-Ortiz F, Simrén J, Dewit N, Vanmechelen E, Zetterberg H, Blennow K, Ashton NJ, Karikari TK. Alzheimers Res Ther. 2022 May 11;14(1):65. doi: 10.1186/s13195-022-01011-w.
Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change.
Smirnov DS, Ashton NJ, Blennow K, Zetterberg H, Simrén J, Lantero-Rodriguez J, Karikari TK, Hiniker A, Rissman RA, Salmon DP, Galasko D. Acta Neuropathol. 2022 Apr;143(4):487-503. doi: 10.1007/s00401-022-02408-5. Epub 2022 Feb 23.
Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
Meyer PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, Köbe T, Gonneaud J, Pichet Binette A, Ozlen H, Yakoub Y, Simrén J, Pannee J, Lantero-Rodriguez J, Labonté A, Baker SL, Schöll M, Vanmechelen E, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S;...
A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer’s disease.
Brum WS, de Bastiani MA, Bieger A, Therriault J, Ferrari-Souza JP, Benedet AL, Saha-Chaudhuri P, Souza DO, Ashton NJ, Zetterberg H, Pascoal TA, Karikari T, Blennow K, Rosa-Neto P, Zimmer ER; Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (N Y)....
The accuracy and robustness of plasma biomarker models for amyloid PET positivity.
Benedet AL, Brum WS, Hansson O; Alzheimer’s Disease Neuroimaging Initiative; Karikari TK, Zimmer ER, Zetterberg H, Blennow K, Ashton NJ. Alzheimers Res Ther. 2022 Feb 7;14(1):26. doi: 10.1186/s13195-021-00942-0.
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease.
Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brum WS, Mathotaarachchi S, Therriault J, Savard M, Chamoun M, Stoops E, Francois C, Vanmechelen E, Gauthier S, Zimmer ER, Zetterberg H, Blennow K, Rosa-Neto P. EBioMedicine. 2022 Feb;76:103836. doi:...
![Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET.](https://karikarilab.org/wp-content/uploads/2022/02/Comparing-tau-status-determined-via-plasma-pTau181-pTau231-and-18FMK6240-tau-PET-400x250.jpg)
Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET.
Tissot C, Therriault J, Kunach P, L Benedet A, Pascoal TA, Ashton NJ, Karikari TK, Servaes S, Lussier FZ, Chamoun M, Tudorascu DL, Stevenson J, Rahmouni N, Poltronetti NM, Pallen V, Bezgin G, Kang MS, Mathotaarachchi SS, Wang YT, Fernandez Arias J, Ferreira PCL,...
Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK, Mollenhauer B, Pilotto A, Lemstra A, Paquet C, Abdelnour C, Kramberger MG, Bonanni L, Vandenberghe R, Hye A, Blennow K, Zetterberg H, Aarsland D; European–Dementia With Lewy Bodies (E-DLB)...
Alzheimer’s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients.
Gerards M, Schild AK, Meiberth D, Rostamzadeh A, Vehreschild JJ, Wingen-Heimann S, Johannis W, Martino Adami P, Onur OA, Ramirez A, Karikari TK, Ashton NJ, Zetterberg H, Blennow K, Maier F, Jessen F. Dement Geriatr Cogn Disord. 2022;51(2):182-192. doi:...
Blood Tests for Alzheimer’s Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.
Karikari TK. J Alzheimers Dis. 2022;90(3):967-974. doi: 10.3233/JAD-215730.
P-tau235: a novel biomarker for staging preclinical Alzheimer’s disease.
Lantero-Rodriguez J, Snellman A, Benedet AL, Milà-Alomà M, Camporesi E, Montoliu-Gaya L, Ashton NJ, Vrillon A, Karikari TK, Gispert JD, Salvadó G, Shekari M, Toomey CE, Lashley TL, Zetterberg H, Suárez-Calvet M, Brinkmalm G, Rosa Neto P, Blennow K. EMBO Mol Med. 2021...
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, Karikari TK, Hourregue C, Cognat E, Dumurgier J, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, Salvadó G, Shekari M, Operto G, Gispert JD, Minguillon C, Fauria K, Kollmorgen G, Suridjan I,...
Prodromal frontotemporal dementia: clinical features and predictors of progression.
Benussi A, Ashton NJ, Karikari TK, Alberici A, Saraceno C, Ghidoni R, Benussi L, Zetterberg H, Blennow K, Borroni B. Alzheimers Res Ther. 2021 Nov 15;13(1):188. doi: 10.1186/s13195-021-00932-2.
Truncating tau reveals different pathophysiological actions of oligomers in single neurons.
Hill E, Karikari TK, Lantero-Rodriguez J, Zetterberg H, Blennow K, Richardson MJ, Wall MJ. Commun Biol. 2021 Nov 4;4(1):1265. doi: 10.1038/s42003-021-02791-x.
Publisher Correction: Microglial activation and tau propagate jointly across Braak stages.
Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, Savard M, Lussier FZ, Tissot C, Karikari TK, Ottoy J, Mathotaarachchi S, Stevenson J, Massarweh G, Schöll M, de Leon MJ, Soucy JP, Edison P, Blennow K, Zetterberg H, Gauthier S, Rosa-Neto P. Nat Med....
Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances.
Chong JR, Ashton NJ, Karikari TK, Tanaka T, Schöll M, Zetterberg H, Blennow K, Chen CP, Lai MKP. J Neurol Neurosurg Psychiatry. 2021 Nov;92(11):1231-1241. doi: 10.1136/jnnp-2021-327370. Epub 2021 Sep 11.
Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias.
Alcolea D, Delaby C, Muñoz L, Torres S, Estellés T, Zhu N, Barroeta I, Carmona-Iragui M, Illán-Gala I, Santos-Santos MÁ, Altuna M, Sala I, Sánchez-Saudinós MB, Videla L, Valldeneu S, Subirana A, Pegueroles J, Hirtz C, Vialaret J, Lehmann S, Karikari TK, Ashton NJ,...
A genome-wide association study of plasma phosphorylated tau181.
Lord J, Zettergren A, Ashton NJ, Karikari TK, Benedet AL, Simrén J; Alzheimer's Disease Neuroimaging Initiative; Hye A, Aarsland D; AddNeuroMed consortium; Blennow K, Zetterberg H, Proitsi P. Neurobiol Aging. 2021 Oct;106:304.e1-304.e3. doi:...
Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer’s disease patients with concomitant cerebrovascular disease.
Chong JR, Ashton NJ, Karikari TK, Tanaka T, Saridin FN, Reilhac A, Robins EG, Nai YH, Vrooman H, Hilal S, Zetterberg H, Blennow K, Lai MKP, Chen CP. Alzheimers Dement. 2021 Oct;17(10):1649-1662. doi: 10.1002/alz.12332. Epub 2021 Mar 31.
Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study.
O'Connor A, Karikari TK, Poole T, Ashton NJ, Lantero Rodriguez J, Khatun A, Swift I, Heslegrave AJ, Abel E, Chung E, Weston PSJ, Pavisic IM, Ryan NS, Barker S, Rossor MN, Polke JM, Frost C, Mead S, Blennow K, Zetterberg H, Fox NC. Mol Psychiatry. 2021...
Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy.
Grothe MJ, Moscoso A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Snellman A, Zetterberg H, Blennow K, Schöll M; Alzheimer's Disease Neuroimaging Initiative. Neurology. 2021 Sep 20;97(12):e1229-e1242. doi: 10.1212/WNL.0000000000012513.
Microglial activation and tau propagate jointly across Braak stages.
Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, Savard M, Lussier FZ, Tissot C, Karikari TK, Ottoy J, Mathotaarachchi S, Stevenson J, Massarweh G, Schöll M, de Leon MJ, Soucy JP, Edison P, Blennow K, Zetterberg H, Gauthier S, Rosa-Neto P. Nat Med....
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, Karikari TK, Vanmechelen E, Zetterberg H, Algeciras-Schimnich A, Knopman DS, Lowe V, Bu G, Vemuri P, Graff-Radford J, Jack CR Jr, Petersen RC. JAMA Neurol. 2021 Sep 1;78(9):1108-1117. doi:...
Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer’s disease.
Alawode DOT, Heslegrave AJ, Ashton NJ, Karikari TK, Simrén J, Montoliu-Gaya L, Pannee J, O Connor A, Weston PSJ, Lantero-Rodriguez J, Keshavan A, Snellman A, Gobom J, Paterson RW, Schott JM, Blennow K, Fox NC, Zetterberg H. J Intern Med. 2021 Sep;290(3):583-601. doi:...
Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome.
Lleó A, Zetterberg H, Pegueroles J, Karikari TK, Carmona-Iragui M, Ashton NJ, Montal V, Barroeta I, Lantero-Rodríguez J, Videla L, Altuna M, Benejam B, Fernandez S, Valldeneu S, Garzón D, Bejanin A, Iulita MF, Camacho V, Medrano-Martorell S, Belbin O, Clarimon J,...